Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17470901 | 1.00 | NOTUM (0.45) | NOTUMKCNJ1MAPTF2ALDH1A1 | |
| SCHEMBL16867046 | 0.81 | NOTUM (0.45) | NOTUMKCNJ1MAPTF2 | |
| SCHEMBL17975491 | 0.81 | NOTUM (0.45) | NOTUMKCNJ1MAPTF2 | |
| SCHEMBL20335609 | 0.80 | KCNJ1 (0.39) | NOTUMKCNJ1 | |
| SCHEMBL20335687 | 0.80 | KCNJ1 (0.39) | NOTUMKCNJ1 | |
| SCHEMBL13823398 | 0.73 | NOTUM (0.63) | NOTUMKCNJ1MAPTF2ALDH1A1 | |
| SCHEMBL969005 | 0.73 | NOTUM (0.53) | NOTUMKCNJ1MAPTF2ALDH1A1 | |
| SCHEMBL17470882 | 0.72 | NOTUM (0.53) | NOTUMKCNJ1MAPTF2ALDH1A1 | |
| SCHEMBL15957096 | 0.72 | NOTUM (0.51) | NOTUMKCNJ1MAPTALDH1A1LMNA | |
| SCHEMBL16122115 | 0.72 | NOTUM (0.41) | NOTUMKCNJ1MAPTF2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765074-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024091-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024091-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NOTUM 4287/4885KCNJ1 2/4885MAPT 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.